In recent years, cannabis has been legalised for medical purposes across most of Europe. However, the European market is still in its infancy and it is therefore essential for players in this sector to be highly reliable with the thorough knowledge, cultivation experience, and scientific guidance needed to produce the highest possible standard of product.
The current and future direction of European cannabis markets
Currently, most growers of cannabis in Europe are fairly new adopters of LED lighting and so may have limited awareness of strategies to optimise yield and quality in their operations. However, this newcomer status within the European market comes with its advantages—such as, the existing proven expertise available to draw upon from other horticultural areas. As the European medical cannabis market gathers pace, it is expected that experts in other crops will diversify into growing cannabis also. To provide an example, chrysanthemums are short-day plants similar to cannabis, so ornamental growers with a proven track record could use their experience and knowledge to make a successful move over to cannabis production. At Fluence, our experts can be available on the ground to facilitate this transition further, offering sound guidance backed by thorough research. Drawing on a combination of their own horticultural knowledge and the long-established cannabis cultivation techniques seen in North America, European growers have all the potential for the success.
At Fluence, we are currently focusing on controlled environments in countries like Switzerland, Portugal, Israel, Netherlands and Denmark that are becoming hotbeds for medical cannabis production. As the markets here are still relatively new, demand for expert insight and best practice is high and this is where we come in. We have a vast install base of over 325,000 square meters of cannabis canopy under our LED lights, which provides us with a wealth of knowledge and experience for cultivators to draw from.
Our skilled horticulture services team across Europe but also in the US and Canada is positioned to provide guidance in cannabis production, speak the growers’ languages, understand the nuances of the local markets and support growers every day in their facilities. No two facilities are the same, so it is essential to provide a bespoke service to suit each customer’s individual operational needs. This is why we emphasise in-person partnerships with growers to adapt the right lighting strategy for each environment, whether that’s a warm-climate greenhouse with a high daily light integral or a cold-climate warehouse that uses 100% supplemental light. We value growers who want data and analytics to understand highly tactical and operationally specific needs like photo acclimation, seasonal production, and compressed cultivation cycles.
In order to achieve the highest possible standards, cultivators must take the time to understand their own business models and products. Do they want to compete in the high-end flower market, or will they focus on extracts and edibles? Do they want to enter the growing CBD market or produce well-rounded cannabis products that fit the needs of physicians and their patients? Pinpointing the needs of the customer upfront will allow growers to deliver a tailored service to satisfy customer demand.
It is also crucial for growers to use trusted research to inform their business decisions and strategy. As an example, we conducted a study with Wageningen University and Research which demonstrated that cultivators who focus on high-end flower production should apply high PPFD levels to enhance plant growth. As facility space is limited and expensive in Europe, maximising capacity is even more crucial. Growing under high PPFD and broad-spectrum lighting can help growers produce consistent, high-quality crops with balanced cannabinoid and terpene profiles.
Fluence’s extensive cannabis research programme in North America is continuing to fuel the market, with new findings that benefit collective understanding of how light impacts cannabis plant production. These findings are shared with the global network of cannabis growers and can be found at https://fluence-led.com/case-studies/.
Customers and patients
Another key point to focus on is consistency. As the profile of medical cannabis continually rises, it is important for cultivators to maintain consistently high standards at all times, regardless of seasonal variations. Greenhouse growers, in particular, should ensure they maintain the same environmental conditions during the winter and summer. If they do not do so, they will achieve different results and the end product will be inconsistent and unreliable for customers.
About Timo Bongartz
Timo Bongartz has spent more than a decade helping businesses transform legacy processes into interconnected digital strategies. His passion for accelerating business transformation—combined with a childhood affinity for cultivation—ultimately led him to the horticulture industry. Today, Bongartz serves as the general manager for Fluence by OSRAM’s EMEA region, empowering food, ornamental and pharmaceutical crop growers across Europe, the Middle East, and Africa to achieve their cultivation goals through advanced horticultural lighting technologies.
Cannabis medication for epileptic girl costs £1k a month
The parents of an epileptic two-year-old are paying £1k a month for medical cannabis they cannot get on the NHS.
Emily Howis and Spencer Carret said the treatment has reduced their daughter Clover’s seizures from 80 a week to just one.
The family, from Trowbridge in Wiltshire, are importing cannabis oil from The Netherlands.
The government said cannabis-based medicine use was being limited due to “ongoing concerns”.
Clover was born with part of her brain missing – known as aicardi syndrome. The genetic condition meant the first three months of her life were blighted by regular epileptic fits.
Mr Carret said she was having “70 to 100” fits a week.
When she was four months old, Clover’s parents paid for an over-the-counter CBD cannabis oil.
Now she has one seizure a week on average, and some weeks none at all, they said.
The couple said it was “incredible” how her life has changed, and that their own neurologist was amazed at her progress.
“They weren’t expecting her to be able to walk or talk, or do anything really,” Mr Carret said.
In 2018, the government said specialist doctors could legally prescribe cannabis oil for medicinal use.
But campaigners said only a handful of families have been successful in the process.
When Clover’s parents applied, they were rejected, so their best hope is for her to be included in a medical research trial.
Family and friends are currently fundraising to help pay for the treatment. Friend Lee Evans is doing a 100,000km (62,000 mile) sponsored run.
But like some other families, the couple said they were worried that restrictions caused by Brexit mean they may soon no longer be able to import cannabis oil from The Netherlands.
The Department of Health said several professional medical bodies “remain concerned” about the lack of evidence around the safety and success of cannabis-based medical products.
A spokesman said: “The NHS is working with the National Institute for Health Research and others to build a high-quality evidence base to determine if patients with refractory epilepsy could benefit from these products.”
NICE, the body that issues prescription guidelines, updated its advice on cannabis-related medical products in March 2021.
The body said it does not want to ban doctors from prescribing medical cannabis to severely epileptic children as this would restrict research, but has stopped short of recommending CBD oils as a widespread treatment for childhood epilepsy.
Cannabis plants are made up of more than 100 different cannabinoids, which have different impacts on the body and are concentrated to different extents in certain parts of the plant.
The most well-known of these are THC and CBD.
THC is the psychoactive cannabinoid – the one that recreational users use to get “high”. CBD does not have this effect.
While almost all cannabinoids are controlled substances under the Misuse of Drugs Act, CBD – or cannabidiol as it is also known – is not.
Image supplied by: https://medcansupport.co.uk/project/clover-emily-and-spencer/
The post Cannabis medication for epileptic girl costs £1k a month appeared first on Weed World Magazine.
Morocco moves to legalise some cannabis cultivation
Privacy and cookies policy
1.1 We are committed to safeguarding the privacy of Weed World magazine visitors and customers.
1.2 This policy applies where we are acting as a data controller with respect to the personal data from weedworldmagazine.org visitors and service users; in other words, where we determine the purposes and means of the processing of that personal data.
2. How we use your personal data
2.1 In this Section 2 we have set out:
(a) the general categories of personal data that we may process;
(b) in the case of personal data that we did not obtain directly from you, the source and specific categories of that data;
(c) the purposes for which we may process personal data; and
(d) the legal bases of the processing.
2.2 We may process data about your use of our website weedworldmagazine.org and services (“usage data”). The usage data may include your IP address, geographical location, browser type and version, operating system, referral source, length of visit, page views and website navigation paths, as well as information about the timing, frequency and pattern of your service use. The source of the usage data is for our analytics tracking system. This usage data may be processed for the purposes of analysing the use of weedworldmagazine.org and services. The legal basis for this processing is our legitimate interests, namely for monitoring and improving our website and services.
2.3 We may process your account data (“account data”). The account data may include your name and email address. The account data may be processed for the purposes of operating our website, providing our product services, maintaining back-ups of our databases and communicating with you. The legal basis for this processing is for our legitimate interests, namely the proper administration of our website weedworldmagazine.org and business.
2.4 We may process information that you post for publication on our website weedworldmagazine.org (“publication data”). The publication data may be processed for the purposes of enabling such publication and administering our website and services. The legal basis for this processing is for our legitimate interests regarding news stories, namely the proper administration of our website and business.
2.5 We may process information relating to transactions, including purchases of goods and services, that you enter into with us and/or through our website weedworldmagazine.org (“transaction data”). The transaction data may include your contact details, your card details and the transaction details. The transaction data may be processed for the purpose of supplying the purchased goods and services and keeping proper records of those transactions. The legal basis for this processing is the performance of a temporary contract between you and us and for taking steps, at your request, to enter into such a contract and our legitimate interests, namely weedworldmagazine.org interest in the proper administration of our website and business.
2.6 We may process information that you provide to us for the purpose of subscribing to our email notifications and/or newsletters (“notification data”). The notification data may be processed for the purposes of sending you the relevant notifications and/or newsletters about weedworldmagazine.org. The legal basis for this processing is consent via you signing up to our newsletter weedworldmagazine.org.
2.7 In addition to the specific purposes for which we may process your personal data set out in this Section 2, we may also process any of your personal data where such processing is necessary for compliance with a legal obligation to which we are subject.
2.8 Please do not supply any other person’s personal data to us, unless we prompt you to do so.
3. Providing your personal data to others
3.1 We may disclose your personal data to any member of our group of companies (this means our subsidiaries, our ultimate holding company and all its subsidiaries) insofar as reasonably necessary for the purposes, and on the legal bases, set out in this policy.
3.2 Financial transactions relating to our website weedworldmagazine.org and services are handled by our payment services providers. We will share transaction data with our payment services providers only to the extent necessary for the purposes of processing your payments, refunding such payments and dealing with complaints and queries relating to such payments and refunds.
3.3 In addition to the specific disclosures of personal data set out in this Section 3, we may disclose your personal data where such disclosure is necessary for compliance with a legal obligation to which we are subject. We may also disclose your personal data where such disclosure is necessary for the establishment, exercise or defence of legal claims, whether in court proceedings or in an administrative or out-of-court procedure.
4. International transfers of your personal data
4.1 In this Section 4, we provide information about the circumstances in which your personal data may be transferred to countries outside the European Economic Area (EEA).
4.2 The hosting facilities for our website are situated in Australia. The European Commission has made an “adequacy decision” with respect to the data protection laws of this country. Appropriate safeguards, namely the use of standard data protection clauses adopted or approved by the European Commission, will protect transfers.
5. Retaining and deleting personal data
5.1 This Section 5 sets out our data retention policies and procedure, which are designed to help ensure that we comply with our legal obligations in relation to the retention and deletion of personal data.
5.2 Personal data that we process for any purpose or purposes shall not be kept for longer than is necessary for that purpose or those purposes.
5.3 We will retain your personal data as follows:
(a) personal data category will be retained for a minimum period of 4 years, and for a maximum period 6 years for financial purposes.
5.4 In some cases it is not possible for us to specify in advance the periods for which your personal data will be retained. In such cases, we will determine the period of retention based on the following criteria:
(a) the period of retention of personal data will be determined based on how long the customer wishes to purchase goods from ourselves and/or if they wish to be taken off our system.
5.5 Notwithstanding the other provisions of this Section 5, we may retain your personal data where such retention is necessary for compliance with a legal obligation to which we are subject, or in order to protect your vital interests or the vital interests of another natural person.
6. Security of personal data
6.1 We will take appropriate technical and organisational precautions to secure your personal data and to prevent the loss, misuse or alteration of your personal data.
6.2 We will store all your personal data on secure servers, personal computers and in secure manual record-keeping systems.
6.3 The following personal data will be stored by us in encrypted form: your name, contact information and some cardholder data.
6.4 Data relating to your enquiries and financial transactions that is sent from your web browser to our web server, or from our web server to your web browser, will be protected using encryption technology.
6.5 You acknowledge that the transmission of unencrypted (or inadequately encrypted) data over the internet is inherently insecure, and we cannot guarantee the security of data sent over the internet.
6.6 You should ensure that your password is not susceptible to being guessed, whether by a person or a computer program. You are responsible for keeping the password you use for accessing our website confidential and we will not ask you for your password (except when you log in to our website).
7.1 We may update this policy from time to time by publishing a new version on our website weedworldmagazine.org.
8. Your rights
8.1 In this Section 8, we have summarised the rights that you have under data protection law. Some of the rights are complex, and not all of the details have been included in our summaries. Accordingly, you should read the relevant laws and guidance from the regulatory authorities for a full explanation of these rights.
8.2 Your principal rights under data protection law are:
(a) the right to access;
(b) the right to rectification;
(c) the right to erasure;
(d) the right to restrict processing;
(e) the right to object to processing;
(f) the right to data portability;
(g) the right to complain to a supervisory authority; and
(h) the right to withdraw consent.
8.3 You have the right to confirmation as to whether or not we process your personal data and, where we do, access to the personal data, together with certain additional information. That additional information includes details of the purposes of the processing, the categories of personal data concerned and the recipients of the personal data. Providing the rights and freedoms of others are not affected, we will supply to you a copy of your personal data. The first copy will be provided free of charge, but additional copies may be subject to a reasonable fee. You can access your personal data by visiting weedworldmagazine.org when logged into our website.
8.4 You have the right to have any inaccurate personal data about you rectified and, taking into account the purposes of the processing, to have any incomplete personal data about you completed.
8.5 In some circumstances you have the right to the erasure of your personal data without undue delay. Those circumstances include: the personal data are no longer necessary in relation to the purposes for which they were collected or otherwise processed; you withdraw consent to consent-based processing; you object to the processing under certain rules of applicable data protection law; the processing is for direct marketing purposes; and the personal data have been unlawfully processed. However, there are exclusions of the right to erasure. The general exclusions include where processing is necessary: for exercising the right of freedom of expression and information; for compliance with a legal obligation; or for the establishment, exercise or defence of legal claims.
8.6 In some circumstances you have the right to restrict the processing of your personal data. Those circumstances are: you contest the accuracy of the personal data; processing is unlawful but you oppose erasure; we no longer need the personal data for the purposes of our processing, but you require personal data for the establishment, exercise or defence of legal claims; and you have objected to processing, pending the verification of that objection. Where processing has been restricted on this basis, we may continue to store your personal data. However, we will only otherwise process it: with your consent; for the establishment, exercise or defence of legal claims; for the protection of the rights of another natural or legal person; or for reasons of important public interest.
8.7 You have the right to object to our processing of your personal data on grounds relating to your particular situation, but only to the extent that the legal basis for the processing is that the processing is necessary for: the performance of a task carried out in the public interest or in the exercise of any official authority vested in us; or the purposes of the legitimate interests pursued by us or by a third party. If you make such an objection, we will cease to process the personal information unless we can demonstrate compelling legitimate grounds for the processing which override your interests, rights and freedoms, or the processing is for the establishment, exercise or defence of legal claims.
8.8 You have the right to object to our processing of your personal data for direct marketing purposes (including profiling for direct marketing purposes). If you make such an objection, we will cease to process your personal data for this purpose.
8.9 You have the right to object to our processing of your personal data for scientific or historical research purposes or statistical purposes on grounds relating to your particular situation, unless the processing is necessary for the performance of a task carried out for reasons of public interest.
8.10 To the extent that the legal basis for our processing of your personal data is:
(a) consent; or
(b) that the processing is necessary for the performance of a contract to which you are party or in order to take steps at your request prior to entering into a contract,
and such processing is carried out by automated means, you have the right to receive your personal data from us in a structured, commonly used and machine-readable format. However, this right does not apply where it would adversely affect the rights and freedoms of others.
8.11 If you consider that our processing of your personal information infringes data protection laws, you have a legal right to lodge a complaint with a supervisory authority responsible for data protection. You may do so in the EU member state of your habitual residence, your place of work or the place of the alleged infringement.
8.12 To the extent that the legal basis for our processing of your personal information is consent, you have the right to withdraw that consent at any time. Withdrawal will not affect the lawfulness of processing before the withdrawal.
8.13 You may exercise any of your rights in relation to your personal data by written notice to us.
9. Third party websites
9.1 Our website includes hyperlinks to, and details of, third party websites.
9.2 We have no control over, and are not responsible for, the privacy policies and practices of third parties.
10. Personal data of children
10.1 Our website weedworldmagazine.org and services are targeted at persons over the age of 18.
10.2 If we have reason to believe that we hold personal data of a person under that age in our databases, we will delete that personal data.
11. Updating information
11.1 Please let us know if the personal information that we hold about you needs to be corrected or updated.
12. Acting as a data processor
12.1 Insofar as we act as a data processor rather than a data controller, this policy shall not apply. Our legal obligations as a data processor are instead set out in the contract between us and the relevant data controller.
Disabled veterans press for access to medical marijuana
Testifying in favor once again was Stephen Mandile, an Army veteran, Uxbridge selectman and longtime medical marijuana advocate who said he used cannabis to end a decade of addiction to opioids prescribed to treat pain from injuries he sustained in Iraq in 2005. A string of other veterans and cannabis activists also touted the bill at Tuesday’s hearing.
The bill (H 179 / S 70) filed by Rep. Michael Soter and Sen. Ryan Fattman would essentially expand the current eligibility criteria for medical marijuana and also create a way that disabled veterans who receive their health care at a federal Veterans Administration facility — and whose doctors therefore cannot legally recommend a medical marijuana prescription — could become eligible.
While anyone 21 or older can buy non-medical marijuana in Massachusetts, registered medical marijuana patients do not have to pay the effective 20 percent tax that is levied on non-medical sales, have access to higher THC dosages for edible products, and can receive discounts from retailers and dispensaries.
Under Soter’s bill, veterans who get their care at the VA could be considered qualifying patients under the state’s medical marijuana law without receiving a diagnosis from a registered physician if they provide their Veterans Administration award letter “indicating an existing disability” to the Cannabis Control Commission. Soter said Illinois and North Dakota already accept VA paperwork in lieu of a doctor’s recommendation.
“The intent of this bill is to allow veterans to submit their Veterans Health Administration paperwork, which confirms having a qualifying condition, [and] removing out-of-pocket costs that veterans are required to spend in order to get a medical card, which is reported as the third-greatest barrier reported by veteran respondents behind cost and access to the right products,” Mandile told the committee.
Soter’s bill would add post-traumatic stress disorder and opioid use disorder to the list of debilitating medical conditions that make someone, veteran or not, eligible to be a medical marijuana patient.
“Currently, Massachusetts is the only state in New England without post-traumatic stress disorder as a qualifying condition. New Mexico was the first state to specifically list PTSD as a qualifying condition in 2009 and, since then, over 25 states have included PTSD as a qualifying condition,” the representative told the committee Tuesday.
Soter’s bill got a hearing before the Cannabis Policy Committee last session, in the weeks just before the COVID-19 pandemic upended the Legislature’s work. Senate Chair Sonia Chang-Diaz said the committee ran out of time to fully vet the idea last session but heard concerns about separating treatment using medical marijuana from a health care provider.
“One of the push-backs that we heard when asking for input from different stakeholders on this legislation was the fear of veteran patients who are suffering from PTSD or other potential maladies for which cannabis might be an appropriate treatment, separating them from the medical attention and counseling that … a non-veteran medical patient would normally have with their primary care provider,” she said. Chang-Diaz added, “That was the concern about this. If you’re getting your care at the VA, but the VA is not allowed to participate in sort of structuring the care plan around use of cannabis.”
Mandile told Chang-Diaz that his VA doctor is aware of and approves of his cannabis use and “would rather me have that than the fentanyl that they can offer me.”
“They are allowed and encouraged to discuss these things and work on an individual basis … with each patient in making sure that they know that they’re not going to lose benefits for being registered in their state marijuana program and help them get as close as they can to where they want to be without having to sign paperwork,” he said, citing a VHA directive.
- smoking1 year ago
A look inside Jim Belushi's 93-acre cannabis farm in Southern Oregon
- benefits of thcv1 year ago
BREAKING: MASSIVE FOOD SHORTAGE ACROSS THE USA – GOVERNMENT WARNING ON CROP LOSS AND WATER SHORTAGE
- Cannabinoids12 months ago
Legal Loophole? Everyone is Buying Legal Delta 9 THC Gummies Online…
- Deals11 months ago
Have You Tried The New High-Potency THCP Vape Cartridges?
- CBD11 months ago
North Carolina Medical Marijuana Legalization Bill Approved by Senators in Committee
- food1 year ago
Cannabis Infused MCT Oil Tincture FOR HIGH THC EDIBLES
- Cannabinoids1 year ago
What Is HHC (Hexahydrocannabinol) and Is It Safe To Use?
- CBD1 year ago
Federal Cannabis Legalization Will Happen Before 2022, According to Rohrabacher
- Education1 year ago
6 milestones in the CBD industry
- smoking1 year ago
THESE CARDANO PROJECTS WILL 100X IN 2021 🚀 (Get In ASAP)